Neuronascent, Inc. (NNI) has discovered and is developing therapies for depression, Down syndrome, post-traumatic stress disorder, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. Our lead candidate for Alzheimer’s disease (AD), NNI-362 has shown great promise in several disease models, with no sign of toxicity or other harmful effects. NNI-362, a small molecule agent promotes new neuron growth in the hippocampus of aged and Down syndrome animal models, a region of the brain where neurons are significantly lost in AD ultimately causing cognitive decline -- a hallmark of the disease. This replacement of neurons lost or reduced, in the hippocampus, along with actual reversal in cognitive deficit in animal models suggests this agent could be neuro-regenerative for AD patients as well. The National Institute on Aging is presently supporting IND safety studies following completion of a pre-IND meeting with the FDA (May 2014).

Each of NNI’s small-molecule, lead therapeutic candidates promote new neurons from the brain’s own neuronal progenitor cell populations in culture and animal models.  The candidates have been optimized to increase neuron numbers in the brain, to improve critical function and to diminish loss of neurons due to disease progression. This ensures that each therapeutic candidate is optimal for a disease indication. In fact, NNI’s depression and post-traumatic stress disorder therapy, NNI-351 is chemically and functionally different than NNI’s neurodegenerative therapeutic, NNI-362, with the former promoting the earliest steps of neurogenesis, while NNI-362 mostly notably promotes the later steps of the neurogenesis process resulting in a neuro-regenerative therapeutic candidate.

Please read on to learn more about the field of neurogenesis and learn how Neuronascent’s lead therapeutics are aimed at disease indications with some of the greatest unmet patient need.


News & Events

Sep 2014 NI Research’s September 2014 Issue of NeuroPerspective fully reviews Alzheimer’s therapeutics and prominently mentions Neuronascent, Inc. In covering the different approaches to Alzheimer’s therapeutic development, the review notes that “The one neurogenesis-focused company prioritizing Alzheimer’s is Neuronascent”.   Click to purchase and download the full issue. NeuroPerspective publisher Dr. Harry Tracy also called Neuronascent “the neurogenesis specialist,” and he selected Neuronascent’s program as one of the ‘Top Ten’ CNS partnering opportunities to be presented at the Informa Therapeutic Area Partnerships conference, which will be held in Boston this November.

Apr 2014  Neuronascent Successfully Completes Pre-IND Meeting with FDA for Alzheimer’s Disease Therapeutic. View Press Release

Mar 2014  Neuronascent to participate in the Redefining Early Stage Investment (RESI) Innovation Challenge, an investment meeting in Boston, MA, March 24, 2014.

Jan 2014  Neuronascent, Inc. Announces Issuance of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate. View Press Release

Nov 2013  Neuronascent, Inc. Alzheimer’s Disease Therapeutic Candidate Selected for Preclinical Safety Testing. View Press Release

More News

 

» Home
» News & Events
» Contact Us
ABOUT US
Management Team
Directors & Advisors
Collaborators
Memberships
TECHNOLOGY
Neurogenesis
Drug Discovery
Intellectual Property
R&D PROGRAMS
Alzheimer's Disease (AD)
Depression
Parkinson's Disease (PD)
Down Syndrome
Ischemia
Hibernation and Ischemia
© 2014 NeuroNascent, Inc. - All Rights Reserved - Website by TeraMark
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.